BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program
BioRestorative Therapies (OTC: BRTX) announced the issuance of a significant patent by the Australian Patent Office for its ThermoStem® Program. The patent covers an implantable scaffold using brown adipose-derived stem cells and methods of use to treat metabolic disorders. Initial preclinical research suggests that increased levels of brown fat can enhance caloric burning and reduce glucose and lipid levels, potentially lowering obesity and diabetes risks. The CEO emphasized the patent's importance for delivery methods in ongoing program development.
- Patent issued for the ThermoStem® Program, enhancing product protection.
- Research indicates that increased brown fat could lead to better metabolic health outcomes.
- None.
Issued Patent Grants Protection for an Implantable Scaffold using Brown Adipose Derived Stem Cells and Methods of Use
MELVILLE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Australian Patent Office has issued the Company a patent related to its metabolic ThermoStem® Program.
Claims granted under the new patent cover an implantable scaffold and brown adipocytes from human brown adipose (fat)-derived stem cells and methods of use. Brown adipocytes are a type of fat tissue found in humans that regulate metabolic activity. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
“Claims granted under this patent are significant as they relate to implantable scaffolds and methods of use in patients suffering from metabolic disorders,” said Lance Alstodt, the Company’s CEO. “As we continue to develop our ThermoStem® program, it is important that we develop methods of delivery, this patent is an important step towards that.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Email: ir@biorestorative.com
FAQ
What does the new patent for BioRestorative Therapies (BRTX) cover?
When was the patent issued for the ThermoStem® Program by BioRestorative Therapies (BRTX)?
How does increased brown fat relate to metabolic health according to BioRestorative Therapies (BRTX)?
What is the significance of the patent for BioRestorative Therapies (BRTX)?
Which program does the issued patent relate to for BioRestorative Therapies (BRTX)?
